In March 2020, Pharmascience announced the launch of its pms-fluticasone propionate/salmeterol DPI, a generic alternative to ADVAIR DISKUS™, in Canada for the treatment of asthma and COPD. It will bring a lower-cost alternative solution to patients.
The company said that the DPI uses the same inhaler device as Advair Diskus. It is one of only two companies launching a generic maintenance treatment for asthma, and the only company offering an inhaler device that both doctors and patients will be familiar with.
According to the Health Canada Drug Product Database, three strengths of pms-fluticasone propionate/salmeterol DPI (100mcg/50mcg, 250mcg/50mcg, and 500mcg/50mcg) are being marketed as of March 5, 2020.
What Generic ADVAIR DISKUS is Used for?
pms-FLUTICASONE PROPIONATE / SALMETEROL DPI (dry powder inhaler) (fluticasone propionate/salmeterol) is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for the maintenance treatment of asthma in patients with reversible obstructive airway disease.
pms-FLUTICASONE PROPIONATE / SALMETEROL DPI (dry powder inhaler) 250 mcg and 500 mcg are indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis, in patients where the use of a combination product is considered appropriate.
Not for Acute Use
pms-FLUTICASONE PROPIONATE / SALMETEROL DPI should not be used to treat acute symptoms of asthma or COPD. It is crucial to inform patients of this and prescribe rapid onset, short duration inhaled bronchodilator (e.g., salbutamol) to relieve the acute symptoms of asthma or COPD.
Patients should be clearly instructed to use rapid onset, short duration, inhaled beta2-agonists only for symptomatic relief if they develop asthma or COPD symptoms while taking pms-FLUTICASONE PROPIONATE / SALMETEROL DPI.
For full instructions on how to use this medication and other important information, please see the complete Product Monograph.
Another Generic Advair Diskus
The U.S. Food and Drug Administration approved the first generic Advair Diskus in January 2019. Pharmaceutical company Mylan got approval to produce and market the combination fluticasone propionate and salmeterol drug, Wixela Inhub at three strengths levels. Available in the same 3 dosage strengths as ADVAIR® DISKUS®.
- Product Name: Wixela® Inhub®
- Brand Reference: ADVAIR® DISKUS® (GSK).
- Therapeutic Class: CORTICOSTEROID – BRONCHODILATOR FOR ORAL INHALATION.
This article is sponsored by CheapoMeds. If you have questions about your prescription medications or any other medication, please contact our team at CheapoMeds by calling toll free 1-844-4CHEAPO (424-3276). One of our patient representatives will be happy to assist you or transfer you to a licensed Canadian pharmacist for a free consultation.
This article contains medical information provided to help you better understand this particular medical condition or process and may contain information about medication often used as part of a treatment plan prescribed by a doctor. It is not intended to be used as either a diagnosis or recommendation for treatment of your particular medical situation. If you are unwell, concerned about your physical or mental state, or are experiencing symptoms you should speak with your doctor or primary health care provider. If you are in medical distress, please contact emergency services (such as 911).